Smolinski, Michael P. team published research in Journal of Medicinal Chemistry in 2018 | 766-11-0

Quality Control of 766-11-0, 5-Bromo-2-fluoropyridine is a useful research compound. Its molecular formula is C5H3BrFN and its molecular weight is 175.99 g/mol. The purity is usually 95%.
5-Bromo-2-fluoropyridine is a boronic acid that has been shown to react with iodides and form 5-bromo-2-fluoroiodobenzene. The reaction of 5-bromo-2-fluoropyridine with benzene gives the same product as the reaction with 1,3,5-trioxane. The UV absorption of 5-bromo-2-fluoropyridine is found at 230 nm and 260 nm. It also has an absorption band in the infrared region at 1625 cm−1. Vibrational progressions have been observed for this molecule, which are due to dipole moments and electron density distributions in the molecule.
5-bromo-2-fluoropyridine is used in the synthesis of heteroaromatic and aniline derivatives of piperidines as potent ligands used for vesicular acetylcholine transport. , 766-11-0.

Pyridine is colorless, but older or impure samples can appear yellow. 766-11-0, formula is C5H3BrFN, Name is 5-Bromo-2-fluoropyridine. The pyridine ring occurs in many important compounds, including agrochemicals, pharmaceuticals, and vitamins. Historically, pyridine was produced from coal tar. Quality Control of 766-11-0.

Smolinski, Michael P.;Bu, Yahao;Clements, James;Gelman, Irwin H.;Hegab, Taher;Cutler, David L.;Fang, Jane W. S.;Fetterly, Gerald;Kwan, Rudolf;Barnett, Allen;Lau, Johnson Y. N.;Hangauer, David G. research published 《 Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)》, the research content is summarized as follows. The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clin. candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clin. trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing standard therapy. Compound 2 is a phase 1 clin. trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models. The discovery strategy for these compounds iteratively utilized mol. modeling, along with the synthesis and testing of increasingly elaborated proof of concept compounds, until the final clin. candidates were arrived at. This was followed with mechanism of action (MOA) studies that revealed tubulin polymerization inhibition as the second MOA.

Quality Control of 766-11-0, 5-Bromo-2-fluoropyridine is a useful research compound. Its molecular formula is C5H3BrFN and its molecular weight is 175.99 g/mol. The purity is usually 95%.
5-Bromo-2-fluoropyridine is a boronic acid that has been shown to react with iodides and form 5-bromo-2-fluoroiodobenzene. The reaction of 5-bromo-2-fluoropyridine with benzene gives the same product as the reaction with 1,3,5-trioxane. The UV absorption of 5-bromo-2-fluoropyridine is found at 230 nm and 260 nm. It also has an absorption band in the infrared region at 1625 cm−1. Vibrational progressions have been observed for this molecule, which are due to dipole moments and electron density distributions in the molecule.
5-bromo-2-fluoropyridine is used in the synthesis of heteroaromatic and aniline derivatives of piperidines as potent ligands used for vesicular acetylcholine transport. , 766-11-0.

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem